Sensus Healthcare (SRTS)

Executive Summary

Sensus Healthcare is a medical device company focused on non-invasive superficial radiotherapy (SRT) for non-melanoma skin cancers and keloids. Its compact, office-based SRT systems offer a precise, pain-free alternative to surgery, reducing patient downtime and scarring. Founded in 2010 and headquartered in Boca Raton, Florida, the company markets two commercial products and serves a growing need as skin cancer incidence rises. With a valuation around $53 million, Sensus targets a niche yet expanding market, leveraging its proprietary technology to improve patient outcomes and reduce healthcare costs. Looking ahead, Sensus is well-positioned to benefit from increased adoption of non-invasive treatments and potential label expansions. Its competitive advantages include established reimbursement, a strong safety profile, and a pipeline targeting additional indications. Key growth drivers include expansion into international markets and positive clinical data that could broaden its addressable patient population. The company’s focus on patient-friendly, cost-effective therapy aligns with healthcare trends favoring outpatient and minimally invasive procedures.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for expanded keloid treatment indication75% success
• Q1 2027Distribution partnership for Asia-Pacific market entry60% success
• Q3 2026Publication of clinical study on keloid recurrence rates with SRT80% success